| abstract |
Proposed prostacyclin compounds and compositions containing prostacyclin compounds. Specifically, prostacyclin compounds containing treprostinyl covalently linked to linear C-C1-6 branched C-C1-6 alkyl, linear C-Salkenyl, branched C-Calkenyl, aryl, aryl-C-C1-6 alkyl, or an amino acid or peptide (for example, dipeptide, tripeptide, tetra-C-C1-6 alkyl, or an amino acid or peptide (for example, a dipeptide, tripeptide, tetra-C-C1-6 alkyl, or an amino acid or peptide (for example, dipeptide, tripeptide, tetryl-C-C1-6 alkyl, or an amino acid or peptide (for example, dipeptide, tripeptide, tetryl-C-C1-6 alkyl, or an amino acid or peptide (for example, dipeptide, tripeptide, tetryl-C-C1-6 alkyl, or an amino acid or peptide (for example, dipeptide, tripeptide, tetryl-C1-C1-6 alkyl, or an amino acid or peptide (for example, dipeptide, tripeptide, tetramethyl C1-C1-6) ). The bond in one embodiment is a carbamate, amide, or ester bond. The proposed prostacyclin compounds may also contain at least one hydrogen atom substituted by at least one deuterium atom. Also proposed methods for the treatment of pulmonary hypertension (for example pulmonary arterial hypertension) and pulmonary hypertension. |